Langley IT Solutions White Rock Surrey Network Maintenance Expert Darren Coleman

Darren Coleman, of Coleman Technologies, was the featured speaker at the Business Expert Forum at Harvard Faculty Club. His company offers high quality IT solutions for any business.

Langley, Canada - September 13, 2017 /NewsNetwork/ —

Cyber security specialist Darren Coleman was a featured speaker at the annual thought leaders conference Business Expert Forum at the Harvard Faculty Club. These thought leaders include CEOs, dignitaries, professionals, best-selling authors, technical and medical experts from around the world.

Colemans’ journey to becoming a best-selling author and speaking at Harvard began with a phone call and a request. To the audience at Harvard he said, “Was it a request or was it an opportunity! You have to bring your ‘A’ game!”

The opportunity was to be a featured contributing author in the book ‘Easy Prey: How to Protect Your Business from Data Breach, Cyber Crime and Employee Fraud’.” The book became a No. 1 best-seller on Amazon.

While public speaking was not his forte` and he wasn’t a stellar student, Coleman said, “To be here speaking at Harvard is truly fantastic.”

We know that a large part of our business comes from referrals from happy, satisfied clients,” said Coleman, “that is why we work so hard to go above and beyond the call of duty.”

Coleman told how he became to own the business that now bears his name and explained the one major stipulation he had to honor. “I had to continue to service and honor all of the existing customers that had warranties and service obligations for which they had already been paid. Looking back, it wasn’t a very big obligation. It’s something I would have done. It’s something I learned from my father,” said Coleman.

Coleman’s advice to the audience at Harvard Faculty Club was as follows: “As entrepreneurs, be willing to commit to your clients, your customers and especially to your family. It’s our commitment that allows us to have things that we cherish. In business, commitment has been the defining factor that has enabled me to survive and thrive.”

Darren Coleman is the owner of Coleman Technologies located in Langley, BC, Canada.

Coleman is a passionate information technology professional, entrepreneur and technology author based in British Columbia. He founded Coleman Technologies in 1999, and since that time has prided himself on his high quality services across a range of areas.

These include consulting, IT management services, computer security, and more. In addition to this, he has achieved certifications as an Information Technology and Computer Support Specialist, as a Certified Ethical hacker, and a Datto Certified Advanced Technician. He has been featured on ABC, NBC, CBS, FOX and CW.

Darren Coleman, of Coleman Technologies, the expert in IT solutions for business across Langley, White Rock and Surrey has appeared as the featured speaker at the Business Expert Forum at Harvard Faculty Club. .

More information can be found at: http://colemantechnologies.com.

Contact Info:
Name: Darren Coleman
Email: darren@coleman.biz
Organization: Coleman Technologies
Address: 6323 197 St #210, Langley, BC V2Y 1K8, Canada

For more information, please visit http://www.colemantechnologies.com

Source: NewsNetwork

Release ID: 238953

Latest News

EU charges Merck KGaA, GE, Canon of misleading merger info

Sep 25, 2017

By Foo Yun CheeBRUSSELS (Reuters) - General Electric , German drugmaker Merck KGaA , and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals.The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules.While the charges will not affect the EU approvals of the deals, they could lead to fines up to 1 percent of global revenue for Merck KGaA and General Electric, and up to...

Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Sep 25, 2017

By Sam NusseyTOKYO (Reuters) - Konica Minolta Inc said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the Japanese firm's healthcare business as it seeks a leading position in precision medicine.The deal is the largest ever for the photocopier maker, which has been seeking to diversify away its office equipment business. It pulled out of cameras about a decade ago.Konica Minolta said its advanced imaging technology complemented privately held Ambry's genetic testing capabilities, with initial applications for combining the technologies seen in...

Oxford BioMedica wins big contract for Novartis cell therapy

Sep 25, 2017

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability.The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukemia that is expected to reach the market this year.A U.S. advisory panel will discuss the case for approving CTL019 at a meeting...

Novartis receives EU approval for Cosentyx label update

Sep 25, 2017

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday. (Reporting by Silke Koltrowitz)

FDA puts hold on Merck multiple myeloma trials after deaths

Sep 25, 2017

(Reuters) - Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.The rare setback for Keytruda sent Merck shares more than 1 percent lower.Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market. Bristol-Myers...

Search
Top News
You May Need To Know

About Us

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales@thehealthierweb.com